PURPLESUN Battles the Invisible Enemy – COVID-19 – There is Light

Company in Partnership with Hackensack Meridian Health and Northwell Health Form a Private Sector Partnership to Provide FMUV Shadowless Delivery Light Decontamination Technology to Government Agencies

September 23, 2020

PURPLESUN Inc. is a technology company on a mission to transform healthcare and provide a sustainable impact for the healthiest environments. Amid the COVID-19 crisis, there is light.

PurpleSun designs and manufactures hospital-grade mechatronic systems that are user friendly and provide a special type of Focused Multivector Ultraviolet (FMUV) light technology, for the purpose of disinfection in 90 seconds.

The company uses proprietary FMUV – focused light energy to improve germicidal effectiveness and speed – to quickly kill off organisms, as proven by several top publications, including the American Journal of Infection Control.

After extensive electrical and ultraviolet light emission testing, including risk mitigation analysis, the PurpleSun E300 was certified to the Standard, IEC 61010-1, by Underwriters Laboratory. The E300 modular and mobile PurpleSun system can be used to treat equipment and rooms while people continue to work around the system safely.

With a community of innovative minds from top executives, clinicians and board members at Hackensack Meridian Health, Northwell Health, and PurpleSun — the trio collaborated to provide access to PurpleSun technology to government agencies in order to help protect the crew and pilots to maximize operational readiness of their no-fail mission criteria.

At Hackensack Meridian Health, a leading not-for-profit health care organization that is the most comprehensive and truly integrated health care network in New Jersey. “We’re proud to help our crew members protect against the common enemy, COVID-19,” said Robert C. Garrett, CEO of Hackensack Meridian Health. “PurpleSun was one of the first investments made through our innovative Bear’s Den incubator program. Now that we’re in the thick of this pandemic, the choice of such an innovative disinfection technology seems more prescient than ever.”

At Northwell Health is New York State’s largest health care provider. “PurpleSun has played an important role in our fight against COVID-19. When the call came to support this initiative, the team stepped up to make the partnership happen – yet another testament to the culture at Northern Westchester Hospital and Northwell Health. Northern Westchester Hospital, along with Staten Island University Hospital and Cohen Children’s Medical Center were the first hospitals to purchase and use PurpleSun in our efforts to enhance disinfection. Having purchased multiple devices, we were able and proud to extend the technology to the government to protect their pilots and crew during this time of crisis,” said Derek Anderson, Executive Director of Northern Westchester Hospital.

SourcePURPLESUN

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”